Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2016 - 2025)

Rocket Pharmaceuticals' Other Accumulated Expenses history spans 10 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 43.45% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 43.45%, while the annual FY2025 figure was $2.3 million, 43.45% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $2.3 million at Rocket Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.1 million in Q2 2024 and bottomed at $482000.0 in Q4 2021.
  • The 5-year median for Other Accumulated Expenses is $1.7 million (2023), against an average of $1.7 million.
  • The largest annual shift saw Other Accumulated Expenses soared 371.58% in 2022 before it plummeted 44.17% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $482000.0 in 2021, then skyrocketed by 371.58% to $2.3 million in 2022, then decreased by 22.04% to $1.8 million in 2023, then fell by 8.3% to $1.6 million in 2024, then skyrocketed by 43.45% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Other Accumulated Expenses are $2.3 million (Q4 2025), $2.7 million (Q3 2025), and $1.7 million (Q2 2025).